UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 2, 2025

EMERGENT BIOSOLUTIONS INC.
(Exact name of registrant as specified in its charter)

Delaware	**001-33137**	**14-1902018**
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

300 Professional Drive,
Gaithersburg, Maryland 20879
(Address of principal executive offices, including zip code)

(240) 631-3200
(Registrant's telephone number, including area code)

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value per share	EBS	New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On August 29, 2025, Emergent BioSolutions Inc. ("Emergent") received a contract modification ("Modification No. 20") of the BARDA AV7909 Contract (as defined below) from the Office of the Assistant Secretary for Preparedness and Response to procure additional doses of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted) (previously known as "AV7909") valued at $30.0 million. This modification relates to Emergent's AV7909 development and procurement contract with the Biomedical Advanced Research and Development Authority ("BARDA"), which became effective on September 30, 2016 (the "BARDA AV7909 Contract") and has been modified from time to time.

The preceding description of Modification No. 20 does not purport to be complete and is qualified in its entirety by reference to the full text of Modification No. 20. Modification No. 20, with relevant redactions to protect confidential and sensitive information, is filed herewith as Exhibit 10.1 and is incorporated herein by reference. The BARDA AV7909 Contract is filed as a material agreement of Emergent as Exhibit 10.57 with Emergent's Annual Report on Form 10-K for the fiscal year ended December 31, 2024.

On September 2, 2025, Emergent issued a press release announcing the contract modification. A copy of the press release is furnished as Exhibit 99.1 to this Current Report and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
10.1	Modification No. 20, effective August 29, 2025 to the BARDA AV7909 Contract.
99.1	Press release issued by Emergent BioSolutions Inc. on September 2, 2025.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EMERGENT BIOSOLUTIONS INC.

Dated: September 5, 2025

By: /s/ RICHARD S. LINDAHL
Name: Richard S. Lindahl
Title: Executive Vice President, Chief Financial Officer and Treasurer

Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions.

AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT

1. CONTRACT ID CODE	PAGE OF PAGES
	1 of 4

2. AMENDMENT/MODIFICATION NO.	3. EFFECTIVE DATE	4. REQUISITION/PURCHASE REQ. NO.	5. PROJECT NO. *(If applicable)*
P00020	See Block 16C	ASP344018	

6. ISSUED BY	CODE	7. ADMINISTERED BY *(If other than Item 6)*	CODE
ASPR-BARDA	ASPR-BARDA	ASPR-BARDA	ASPR-BARDA
200 Independence Ave., S.W.		200 Independence Ave., S.W.	
Room 640-G		Room 638-G	
Washington DC 20201		Washington DC 20201	

8. NAME AND ADDRESS OF CONTRACTOR *(No., street, county, State and ZIP Code)*

EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.
EMERGENT PRODUCT DEVELOPMENT GAITHE
300 PROFESSIONAL DR # 100
GAITHERSBURG MD 208793419

CODE 1365869 FACILITY CODE

(x) 9A. AMENDMENT OF SOLICITATION NO.

9B. DATED *(SEE ITEM 11)*

x 10A. MODIFICATION OF CONTRACT/ORDER NO. HHSO100201600030C

10B. DATED *(SEE ITEM 13)* 09/30/2016

11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS

☐ The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offers ☐ is extended. ☐ is not extended.
Offers must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended , by one of the following methods: (a) By completing Items 8 and 15, and returning _____ copies of the amendment; (b) By acknowledging receipt of this amendment on each copy of the offer submitted ; or (c) By separate letter or electronic communication which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGEMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted , such change may be made by letter or electronic communication, provided each letter or electronic communication makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.

12. ACCOUNTING AND APPROPRIATION DATA *(If required)* Net Increase: $30,000,000.00
2025.Q99BASN.26088

13. THIS ITEM ONLY APPLIES TO MODIFICATION OF CONTRACTS/ORDERS. IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.

CHECK ONE	
	A. THIS CHANGE ORDER IS ISSUED PURSUANT TO: *(Specify authority)* THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.
	B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES *(such as changes in paying office, appropriation data, etc.)* SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b).
X	C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF: FAR Part 43.103(a) - Bilateral Modifications
	D. OTHER *(Specify type of modification and authority)*

E. IMPORTANT: Contractor ☐ is not ☒ is required to sign this document and return 1 copies to the issuing office.

14. DESCRIPTION OF AMENDMENT/MODIFICATION *(Organized by UCF section headings, including solicitation/contract subject matter where feasible.)*

Tax ID Number: [**]
UEI: CNPVCR8DK7M8
The purpose of this modification is to Exercise CLIN 0011E.

ARTICLES B.3 OPTION PRICES, B.5. ADVANCE UNDERSTANDINGS, ARTICLE C.1. STATEMENT OF WORK, and SECTION J- LIST OF ATTACHMENTS are revised.

Funds Obligated Pior to this Modification: $[**]
Funded via Mod #20: $[**]
Total Funds Obligated to Date: $[**]

Continued ...

Except as provided herein, all terms and conditions of the document referenced in Item 9 A or 10A, as heretofore changed, remains unchanged and in full force and effect.

15A. NAME AND TITLE OF SIGNER *(Type or print)*	16A. NAME AND TITLE OF CONTRACTING OFFICER *(Type or print)*
Paul Williams SVP, Products Business	YIFAN YANG

15B. CONTRACTOR/OFFEROR	15C. DATE SIGNED	16B. UNITED STATES OF AMERICA	16C. DATE SIGNED
Electronically signed by: Paul Williams Reason: I approvethis document Date: Aug 29, 2025 09:27:55 EDT	08/29/2025	Yifan Yang -S Digitally signed by Yifan Yang -S Date: 2025.08.29 17:05:40 -04'00'	
(Signature of person authorized to sign)		*(Signature of Contracting Officer)*	

Previous edition unusable

STANDARD FORM 30 (REV. 11/2016)
Prescribed by GSA FAR (48 CFR) 53.243

NAME OF OFFEROR OR CONTRACTOR
EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. 1365869

ITEM NO. (A)	SUPPLIES/SERVICES (B)	QUANTITY (C)	UNIT (D)	UNIT PRICE (E)	AMOUNT (F)
	All other terms and conditions remain unchanged. OTA: N Appr. Yr.: 2025 CAN: Q99BASN Object Class: 26088 Period of Performance: 09/30/2016 to 09/29/2026 Add Item 15 as follows:				
15	CLIN 0011E Additional Surge Capacity (Licensure) Obligated Amount: $[**]				[**]

The purpose of this modification is to modify ARTICLES B.3 OPTION PRICES, B.5. ADVANCE UNDERSTANDINGS, ARTICLE C.1. STATEMENT OF WORK, and SECTION J- LIST OF ATTACHMENTS

ARTICLE B.3. OPTION PRICES – CLIN 0011 is modified as follows:

CLIN	Period of Performance	Supplies/ Services	Estimated Doses	Price per Dose	Total Not to Exceed Cost
0011E **(Option Quantity)	08/29/2025 through 3/31/2026	Additional Surge Capacity (Licensure)	[**]	$[**] ([**] months from date of manufacture)	$[**] (Funded)
			[**]	$[**] ([**] months from date of manufacture)	

*Under **CLIN 0011E** a total of [**] estimated doses are expected to be procured at the unit prices stated above. Each vial contains [**] doses; a credit will be issued on the final invoice for any doses delivered above $[**]. The exact quantity within each pricing tier is subject to change depending on timing of delivery. ** Delivery of Doses supplied under CLIN 0011E shall not occur prior to October 1, 2025.

ARTICLE B.5. ADVANCE UNDERSTANDINGS – is modified as follows:

p. CLIN 0011E

• For CLIN 0011E, BARDA agrees to receiving doses that are more than [**] months but not exceeding [**] months from their date of manufacture (Reduced Shelf-Life Doses).

• These anthrax vaccine doses will have two different unit prices depending on the age of the vaccine post-manufacture. Vaccine doses delivered up to or equal to [**] months from their manufacture date will be charged a dose price of $[**] per dose. Vaccines delivered with a reduced shelf life greater than [**] months, but less than or equal to [**] months post-manufacture will be charged a unit dose price of $[**] per dose.

The following table is provided as an estimate of doses to be delivered under CLIN 011E but subject to change:

Product	Period of Performance	Estimated Quantity for Delivery
Base Doses	[**] months from date of manufacture	[**]
Reduced Shelf-Life Doses	[**] months but [**] months from date of manufacture	0

End of Modification #20

SECTION C DESCRIPTION/SPECIFICATIONS/WORK STATEMENT

ARTICLE C.1. STATEMENT OF WORK is modified as follows:

Independently and not as an agent of the Government, the Contractor shall furnish all necessary services, qualified personnel, material, equipment, and facilities not otherwise provided by the Government as needed to perform the Statement of Work dated August 2025, set forth in SECTION J List of Attachments, attached hereto and incorporated into this Prime Contract.

SECTION J LIST OF ATTACHMENTS is modified as follows:

1. Statement of Work, dated August 2025, 10 pages

Exhibit 99.1

Emergent BioSolutions Awarded $30 Million Contract Modification for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted), a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use

GAITHERSBURG, Md., September 2, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has received a $30 million contract modification from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), to supply CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted). Deliveries are expected to begin this calendar year and are scheduled to be completed by March 2026.

"This new contract modification is the next step in our ongoing engagement with the U.S. government, with the shared goal to help ensure medical countermeasures, like CYFENDUS® vaccine, are readily available to safeguard civilian populations against the potential threat of anthrax," said Paul Williams, senior vice president, head of products business, global government & public affairs at Emergent. "We're proud to leverage a U.S.-based supply chain for our anthrax vaccines, as we believe this is critical to Emergent's leadership and continued support of the U.S. government's national security priorities."

Anthrax is a Tier 1 biological threat due to its potential to be used for a bioterrorist incident and threat to public health and national security. CYFENDUS® vaccine was approved by the U.S. Food and Drug Administration in July 2023 as a two-dose anthrax vaccine for post-exposure prophylaxis use in individuals 18 through 65 years of age when given with recommended antibacterial drugs.

This follows a previously announced contract modification of $50 million to supply CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted) in December 2024. This project has been supported in whole or in part with federal funds from the U.S. Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority, under contract HHSO100201600030C.

About CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)

Indication

CYFENDUS® (Anthrax Vaccine Absorbed, Adjuvanted) is a vaccine indicated for post-exposure prophylaxis of anthrax disease following suspected or confirmed exposure to *Bacillus anthracis* in persons 18 through 65 years of age when given with recommended antibacterial drugs. The efficacy of CYFENDUS® vaccine for post-exposure prophylaxis (PEP) is based solely on studies in animal models of inhalational anthrax.

Important Safety Information

Contraindication: Do not administer CYFENDUS® to individuals with a history of a severe allergic reaction (e.g., anaphylaxis) following a previous dose of CYFENDUS®,

BioThrax® (a licensed anthrax vaccine with the same active ingredient as CYFENDUS®) or any component of the vaccine.

Warnings and Precautions: *Management of Acute Allergic Reactions*: Appropriate medical treatment must be available to manage possible anaphylactic reactions following administration of CYFENDUS®. *Pregnancy*: CYFENDUS® can cause fetal harm when administered to a pregnant individual. In an observational study, there were more birth defects in infants born to individuals vaccinated with BioThrax® (a licensed anthrax vaccine with the same active ingredient as CYFENDUS®) in the first trimester compared to infants born to individuals vaccinated post pregnancy or individuals never vaccinated with BioThrax®.

Adverse Reactions: The most common (≥10%) injection-site adverse reactions reported were tenderness, pain, arm motion limitation, warmth, induration, itching, swelling, and erythema/redness. The most common systemic adverse reactions were muscle aches, tiredness, and headache. To report Suspected Adverse Reactions, contact Emergent BioSolutions at 1-800-768-2304 or medicalinformation@ebsi.com; or VAERS at 1-800-822-7967 or www.vaers.hhs.gov.

Please see the Prescribing Information for CYFENDUS® for full safety information.

About Emergent BioSolutions
At Emergent, our mission is to protect and save lives. For over 25 years, we've been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today's health challenges and tomorrow's threats, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify.

Safe Harbor Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including statements regarding the expected timing for delivery of the CYFENDUS® vaccine and Emergent's ability to increase inventories of CYFENDUS ® vaccine to meet requested levels within specified time frames, are forward-looking statements. We generally identify forward-looking statements by using words like "anticipate," "believe," "continue," "could," "estimate," "expect," "forecast," "goal," "intend," "may," "plan," "should," "will," "would," and similar expressions or variations thereof, or the negative thereof, but these terms are not the exclusive means of identifying such statements. Forward-looking statements are based on our current intentions, beliefs, and expectations regarding future events based on information that is currently available. We cannot guarantee that any forward-looking statement will be accurate. Readers should realize that if underlying assumptions prove inaccurate or if known or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Readers are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, we do not undertake

to update any forward-looking statement to reflect new information, events, or circumstances. Readers should consider this cautionary statement, as well as the risk factors identified in our periodic reports filed with the U.S. Securities and Exchange Commission, when evaluating our forward-looking statements.

Investor Contact:
Richard S. Lindahl
Executive Vice President, CFO
lindahlr@ebsi.com

Media Contact:
Assal Hellmer
Vice President, Communications
mediarelations@ebsi.com